Syntheses of LSD1/HDAC Inhibitors with Demonstrated Efficacy against Colorectal Cancer: In Vitro and In Vivo Studies Including Patient-Derived Organoids

Researchers designed a series of dual LSD1-HDAC inhibitors. One of those compounds demonstrate significant antitumor activity against colorectal cancer, better than irinotecan, and effectively inhibits growth in patient-derived colorectal cancer organoids.